Assenagon Asset Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $331K | Sell |
22,136
-590
| -3% | -$8.83K | ﹤0.01% | 1060 |
|
|
2025
Q1 | $367K | Buy |
22,726
+74
| +0.3% | +$1.19K | ﹤0.01% | 1039 |
|
|
2024
Q4 | $527K | Sell |
22,652
-1,120,116
| -98% | -$26.1M | ﹤0.01% | 1169 |
|
|
2024
Q3 | $33.6M | Buy |
+1,142,768
| New | +$33.6M | 0.06% | 217 |
|
|
2024
Q2 | – | Sell |
-64,400
| Closed | -$2.44M | – | 1449 |
|
|
2024
Q1 | $2.44M | Buy |
+64,400
| New | +$2.44M | 0.01% | 797 |
|
|
2023
Q2 | – | Sell |
-12,738
| Closed | -$92.4K | – | 1413 |
|
|
2023
Q1 | $92.4K | Hold |
12,738
| – | – | ﹤0.01% | 1342 |
|
|
2022
Q4 | $143K | Hold |
12,738
| – | – | ﹤0.01% | 1273 |
|
|
2022
Q3 | $168K | Sell |
12,738
-12,975
| -50% | -$171K | ﹤0.01% | 1237 |
|
|
2022
Q2 | $325K | Buy |
25,713
+4,787
| +23% | +$60.5K | ﹤0.01% | 1263 |
|
|
2022
Q1 | $1.2M | Buy |
20,926
+4,279
| +26% | +$246K | ﹤0.01% | 977 |
|
|
2021
Q4 | $1.98M | Buy |
16,647
+5,964
| +56% | +$708K | 0.01% | 795 |
|
|
2021
Q3 | $2.12M | Sell |
10,683
-600
| -5% | -$119K | 0.01% | 638 |
|
|
2021
Q2 | $1.96M | Buy |
11,283
+5,371
| +91% | +$934K | 0.01% | 651 |
|
|
2021
Q1 | $1.17M | Sell |
5,912
-523
| -8% | -$104K | ﹤0.01% | 858 |
|
|
2020
Q4 | $1.27M | Buy |
6,435
+1,581
| +33% | +$311K | 0.01% | 623 |
|
|
2020
Q3 | $860K | Sell |
4,854
-8,455
| -64% | -$1.5M | ﹤0.01% | 844 |
|
|
2020
Q2 | $3.08M | Buy |
+13,309
| New | +$3.08M | 0.02% | 436 |
|
|
2019
Q4 | – | Sell |
-512
| Closed | -$98K | – | 886 |
|
|
2019
Q3 | $98K | Sell |
512
-7,800
| -94% | -$1.49M | ﹤0.01% | 757 |
|
|
2019
Q2 | $1.42M | Buy |
8,312
+4,551
| +121% | +$779K | 0.01% | 589 |
|
|
2019
Q1 | $757K | Buy |
+3,761
| New | +$757K | 0.01% | 707 |
|